louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01301859: Personalized Antidepressant Adherence Strategies For Depressed Elders
Official title: Treatment Initiation and Participation Program (TIP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Keywords: older adults
adherence
antidepressant
depression
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
name: University of Michigan
First posted: 2011-02-23
Enrollment: 231
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The study is a randomized controlled trial to test the usefulness of a brief intervention to improve adherence to antidepressant medication prescribed to older adults in a primary care setting. Study will be conducted at Weill Cornell and University of Michigan.

Detailed description: The intervention is a brief, psychosocial intervention designed to be an adjunct to pharmacotherapy prescribed by a primary care physician. It includes psychoeducation, problem solving and development of goals and a personalized adherence strategy. The intervention includes three 30 minute sessions during the first 6 weeks of treatment and a follow-up phone call two weeks later.

Eligibility criteria: Inclusion Criteria:

Age: 65 and older; Newly prescribed antidepressant medication by PCP (within past 10 days); Has not been prescribed antidepressant medication in previous 6 months.

Exclusion Criteria:

High suicide risk, i.e. intent or plan to attempt suicide Presence of alcohol abuse, substance abuse, psychotic disorder or, bipolar disorder as observed on the SCID, are excluded; Dementia: MMSE below 24, clinical assessment, or medication; Inability to speak English; Aphasia interfering with communication; Terminal illness or current chemotherapy

-

Primary outcomes:
measure: Brief Medication Questionnaire
timeFrame: 12 week Follow up
Secondary outcomes:
measure: Hamilton Depression Rating Scale
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: New York
country: United States
facility: Weil Cornell Medical College
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: JoAnne Sirey, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sirey JA, Banerjee S, Marino P, Bruce ML, Halkett A, Turnwald M, Chiang C, Liles B, Artis A, Blow F, Kales HC. Adherence to Depression Treatment in Primary Care: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Nov 1;74(11):1129-1135. doi: 10.1001/jamapsychiatry.2017.3047.
Clinical trial NCT01110759: Medical Review: Hand Surgery After Local Block Versus Non-block
Official title: Retrospective Chart-review Study Involving Outpatients Who Underwent Hand Surgery With Local Anesthesia: Comparing Outcome With a Peripheral Nerve Block vs. Local Infiltration Alone
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carpal Tunnel Syndrome
Keywords: pain management
ambulatory surgery
opioid
local anesthesia
hand surgery
postoperative pain
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
First posted: 2010-04-27
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatients undergoing hand surgery

Brief summary: In this study, the effects of local block vs non block will be assessed with respect to postoperative outcomes (such as pain score, and recovery profiles) in outpatients after hand surgery.

Detailed description: Analyzing medical records and through a telephone questionnaire, in a retrospective and prospective review respectively.

Eligibility criteria: Inclusion Criteria:

* 18-80 years old
* Outpatients who underwent hand surgery under peripheral nerve block or local infiltration alone

Exclusion Criteria:

* Patients who do not meet inclusion criteria

Primary outcomes:
measure: postoperative pain
timeFrame: hours to months
Secondary outcomes:
measure: Nausea
timeFrame: days to weeks
measure: Vomiting
timeFrame: dias to weeks
Other outcomes:
measure: Outcomes
timeFrame: days to weeks
Locations:
city: Los Angeles
country: United States
facility: Cedars Sinai Medical Center
state: California
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Ronald H Wender, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03405259: A Clinical Study to Compare Professional Treatments for Dentinal Hypersensitivity
Official title: A Pilot Clinical Study to Compare Professional Treatments for Dentinal Hypersensitivity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dentinal Hypersensitivity
Lead sponsor: Procter and Gamble
Sponsor class: INDUSTRY
First posted: 2018-01-23
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to compare professional treatments for dentinal hypersensitivity immediately following a single, professionally-applied treatment and again approximately 2 months following treatment.


Eligibility criteria: Inclusion Criteria:

* be at least 18 years of age;
* provide written informed consent prior to participation and be given a signed copy of the informed consent form;
* be in good general health as determined by the Investigator/designee; and
* have at least one tooth with a VAS score of greater than or equal to 30 in response to the air challenge.

Exclusion Criteria:

* allergy to rosin or to pine nuts;
* self-reported pregnancy or nursing;
* severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession;
* active treatment for periodontitis;
* fixed facial orthodontic appliances;
* any diseases or conditions that might interfere with the safe completion of the study; or
* an inability to undergo any study procedures.

Primary outcomes:
measure: Change From Baseline Air Challenge
timeFrame: Within 5 minutes after treatment was applied
measure: Change From Baseline Visual Analog Scale
timeFrame: Within 5 minutes after treatment was applied
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00332059: Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2006-06-01
Enrollment: 445
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of glaucoma or ocular hypertension in both eyes
* Patient requires IOP-lowering drug in both eyes

Exclusion Criteria:

* Uncontrolled medical conditions
* Contraindication to beta-adrenoceptor antagonist therapy

Primary outcomes:
measure: IOP
Secondary outcomes:
Other outcomes:
Locations:
city: Bel Air
country: United States
state: Maryland
city: Vienna
country: Austria
city: Montreal
country: Canada
state: Quebec
city: Berlin
country: Germany
Study officials:
References:
Clinical trial NCT05473559: Comparison Between the Effect of Infiltration Between the Popliteal Artery and Capsule of the Knee Block Versus Selective Tibial Nerve Block for Postoperative Analgesia in Patient Undergoing Total Knee Arthroplasty. A Prospective Randomized Study
Official title: Comparison Between i Pack Block and Post Tibial Nerve Block
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Analgesia
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2022-07-26
Enrollment: 70
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Comparison Between the Effect of Infiltration Between the Popliteal Artery and Capsule of the Knee Block Versus Selective Tibial Nerve Block for Postoperative Analgesia in Patient Undergoing Total Knee Arthroplasty.


Eligibility criteria: Inclusion Criteria:

* Patients with osteoarthritis scheduled for a primary either partial or total knee arthroplasty • Patients aged 40-80 years with a body mass index of 18-36 kg/ m2 and an American Society of Anesthesiologists functional status of I-III Planned use of regional anesthesia

Exclusion Criteria:

* • Patients younger than 40 years old and older than 80years.

  * Hepatic or renal insufficiency.
  * Patients undergoing general anesthesia.
  * Allergy or intolerance to one of the study medications.
  * BMI \> 36
  * Diabetes
  * ASA of IV
  * Chronic opioid use (taking opioids for longer than 3 months, or daily oral morphine equivalent of \>5mg/day for one month)

Primary outcomes:
measure: Total morphine consumption
timeFrame: 24 hours post operative
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta university
Study officials:
affiliation: Tanta University
name: Marwa Abogabal, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tanta University
name: Wafaa Abdelwahed, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kafr Elsheikh university
name: Wafaa Abdelsalam, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tanta University
name: Shaimaa Zahra
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05153759: EMS Providers' Health Initiative Study
Official title: EMS Providers' Health Initiative Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Shift-work Disorder
Keywords: EMS
Night shift
Nutrition
Insulin resistance
Circadian rhythm
Lead sponsor: State University of New York at Buffalo
Sponsor class: OTHER
First posted: 2021-12-10
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to explore dietary factors that influence glycemic control in night shift EMS providers and to test the feasibility of a dietary intervention among these providers.

Detailed description: This study can be broken down into two phases. Both phases will take place over the course of 3 weeks. During the first week, participants will be scheduled for a single 60-90 minute zoom appointment. During this appointment, informed consent will be obtained, participants will provide health and demographic information, complete several questionnaires, and be familiarized with study protocols. The following week, participants will wear a continuous glucose monitor, actigraph activity monitor, document everything they have to eat and drink, and rate their daily stress levels. Participants will continue this during the final week and will be randomized to consume either a 2:1 or 1:1 protein to carbohydrate ratio during the night shift during this week.

Eligibility criteria: Inclusion Criteria:

* Emergency medical service (EMS) provider
* Works night shift only for at least one year
* Provides patient care as primary duty

Exclusion Criteria:

* Diagnosis of a metabolic disease (i.e. diabetes, prediabetes, metabolic syndrome)
* Taking medication to lower blood glucose
* Pregnant or planning to become pregnant
* Diagnosis of kidney disease or impairment
* Allergies or intolerances to study foods
* Digestive disorder

Primary outcomes:
measure: Glycemic control
timeFrame: Two weeks
measure: Compliance
timeFrame: Four days
Secondary outcomes:
measure: Perceived stress
timeFrame: Two weeks
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: University at Buffalo
state: New York
Study officials:
affiliation: University at Buffalo
name: David Hostler, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01734759: Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits
Official title: Influence of Medication Palatability on Prescribing Habits of Pediatric Prescribers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: medication palatability
medication taste
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-11-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to see if a medication taste test influences the prescribing habits of pediatric prescribers at Mayo Clinic.


Eligibility criteria: Inclusion Criteria:

* subjects possess prescriptive authority (e.g. MD, nurse practitioner, physician's assistant, medication therapy management pharmacists)
* subjects have prescribed at least one of the study medications from one of the medication classes to pediatric patients at an outpatient clinic in the three months preceding the study

Exclusion Criteria:

* subjects do not prescribe any of the tested medications
* subject has an allergy to all of the study medications
* subject is pregnant or breastfeeding
* subject has a medical condition that prevents them from being involved in the taste test

Participants are advised to be within or accessible to the Rochester, MN area during study recruitment and accessible afterwards via mail, email or fax.

Primary outcomes:
measure: Taste scores on the visual analog scale
timeFrame: Change from baseline in taste scores at 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Bernard Lee, PharmD, RPh
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Ole J Olson, Pharm.D., BCPS
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Michelle J LoTurco, Pharm.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02150759: Dexmedetomidine-ketamine in Femur Proximal Fracture Patients
Official title: Comparison Study of Analgesic Effects for Dexmedetomidine-fentanyl vs Dexmedetomidine-ketamine in Femur Proximal Fracture Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: Dexmedetomidine
Ketamine
Pain
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2014-05-30
Enrollment: 46
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: * Comparison study of analgesic effects for dexmedetomidine-fentanyl vs dexmedetomidine-ketamine
* lateral position for spinal anesthesia in femur proximal fracture patients

Detailed description: * Dexmedetomidine (1mcg/kg)- fentanyl (1mcg/kg) vs dexmedetomidine (1mcg/kg) - ketamine (1mg/kg) 10 minutes loading.
* After 10 minutes of drug infusion, patients are prepared for spinal anesthesia.
* pain scale and quality of patient positioning are measured three times (lateral position, chest-knee position, intrathecal local anesthetics injection)
* When patients have severe pain during intraoperative period, fentanyl 50 mcg will be intravenously inject.
* Patients will be injected propofol 10mg when they have agitation signs during operation.
* vital signs, bispectral index, korean version of mini mental status examination, verbal rating scale,fentany/propofol consumption, frequency of intrathecal injection

Eligibility criteria: Inclusion Criteria:

* American society of anesthesiologists classification 1-3 patients
* \>20 years old

Exclusion Criteria:

* patients refuse
* dementia patients, cooperation difficult patients
* anaphylaxis of dexmedetomidine, ketamine, local anesthetics
* heart problem (bradycardia, atrioventricular block)

Primary outcomes:
measure: Pain Score Using Five Scales
timeFrame: average 10-20 minutes
Secondary outcomes:
measure: Quality of Patient Positioning
timeFrame: average 10-20 minutes during spinal anesthesia
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Haeundae paik hospital, inje university
Study officials:
affiliation: Inje University
name: Sang Eun Lee, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03428659: Functional Recovery Changes in Subacute Stroke Patients
Official title: Dynamic Time Series Data Collection for Functional Recovery Changes in Sub-acute Stroke Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sub-acute Stroke
Keywords: Motor function
Recovery
Gait
Magnetic resonance imaging
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2018-02-09
Enrollment: 94
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A person who was inpatient at sub-acute stage at the Samsung Medical Center.

Brief summary: In subacute stroke patients, dynamic time series data of brain imaging and motor function measurement were obtained from 7 days to 6 months (total 9 times) after stroke onset


Eligibility criteria: Inclusion Criteria:

* at least 19 years of age hemiplegic stroke patients
* Subacute-phase ischemic or hemorrhagic stroke patients within 7 days of onset
* Functional Ambulation Category Scale (FAC) of 3 or less, 7 days of onset,
* A person who understands and voluntarily participates in this study and signs a research agreement

Exclusion Criteria:

* User of artificial heartbeat
* Patients with claustrophobia
* Patients with metal implants
* Patients who are contraindicated for other common MRI
* Patients with mild motor impairment with an FMA score of 80 or higher
* Patients whose conscious state is coma and who have no response at all
* Patients who can not independently gait with the Modified Rankin Scale (mRS) score of 4 or more before the onset of disease

Primary outcomes:
measure: Mechanism of recovery of motor function according to recovery of sub-acute stroke
timeFrame: Through study completion, an average of 6 months
measure: Mechanism of recovery of gait function according to recovery of sub-acute stroke
timeFrame: Through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
Clinical trial NCT02278159: Evaluation of the Integrated Home Dialysis Model
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Failure, Chronic
Keywords: end-stage kidney disease
peritoneal dialysis
home hemodialysis
technique survival
patient survival
Lead sponsor: Princess Alexandra Hospital, Brisbane, Australia
Sponsor class: OTHER
Collaborators: name: Baxter Healthcare Corporation
First posted: 2014-10-29
Enrollment: 11600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with home dialysis as the first renal replacement therapy \[RRT\] modality (defined by the dialysis modality at 90 days) in Australia and New Zealand as reported in Australia and New Zealand Dialysis and Transplant Registry \[ANZDATA\]

Brief summary: The purpose of this study is to evaluate which home dialysis modality pattern (home hemodialysis \[HHD\], peritoneal dialysis \[PD\] or a combination of both, e.g. PD and then HHD) allows for the longest home dialysis survival, as defined by the time dialysed in a home environment. The investigators hypothesize that patients transferred from one home modality to another will have a longer home dialysis survival compared to patients treated only with PD or HHD.


Eligibility criteria: Inclusion Criteria:

* Patients with PD/HHD 90 days after RRT initiation between January 1, 2000 and December 31, 2012 reported in ANZDATA
* ≥ 18 years

Exclusion Criteria:

* Less than 90 days of dialysis
* \< 18 years
* Patients transferred to Australia/New Zealand after initiation of dialysis in another country

Primary outcomes:
measure: Home dialysis survival
timeFrame: Survival analysis; specific analysis at 5 years after dialysis initiation
Secondary outcomes:
measure: Patient survival, censored for technique failure
timeFrame: Survival analysis, specific analysis at 1,2 5 years after dialysis initiation
measure: Home technique survival, censored for death
timeFrame: survival analysis, specific analysis at 1,2 5 years after dialysis initiation
Other outcomes:
measure: Home dialysis survival, case-control analysis
timeFrame: survival analysis, specific analysis at 1,2 5 years after dialysis initiation
Locations:
Study officials:
References:
Clinical trial NCT05862259: A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
Official title: A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Malignant Tumor
Immunotherapy
Artificial Intelligence
Lead sponsor: Xinqiao Hospital of Chongqing
Sponsor class: OTHER
First posted: 2023-05-17
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: receiving immunotherapy

Brief summary: In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy


Eligibility criteria: Inclusion Criteria:

1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
3. the stage IV according to the eighth edition of IASLC.
4. PS 0-2, the expected survival \> 3 months.
5. the age of 18-75 years.
6. no contraindication to treatment with immune checkpoint inhibitors.

Exclusion Criteria:

1. the patients' compliance was poor, which violated the rules of the trial;
2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
3. the patients with other malignant tumors;
4. the researchers considered that the patients should not participate in other conditions of the trial.

Primary outcomes:
measure: Progression-free survival
timeFrame: six months
Secondary outcomes:
measure: Overall survival
timeFrame: two years
measure: Objective response rate
timeFrame: one years
measure: Immune-Related Adverse Events
timeFrame: two years
Other outcomes:
measure: Indicators of cardiac injury
timeFrame: two years
Locations:
city: Chongqing
country: China
facility: the second affiliated hospital of Army medical university
state: Chongqing
Study officials:
References: